In this episode of the podcast “Hope and Help Happen Here: A Pediatric Cancer Podcast,” Bionaut CEO Michael Shpigelmacher talks about the promise Bionauts offer in the treatment of one of the most difficult forms of pediatric cancer—Diffuse Intrinsic Pontine Gliomas.
Agence France-Presse, the world’s largest news agency, recently profiled Bionaut’s work. The article has been published globally and has received more than 130 million views.
Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors LOS ANGELES and NEEDHAM, Mass., December 15, 2021 (GLOBE NEWSWIRE)…
First-in-class Bionaut™ treatment modality will use remote-controlled microscale robots to treat rare pediatric neurological disorder Company also appoints renowned expert in targeted therapeutics and former Kite CEO Aya Jakobovits, Ph.D.,…
The U.S. Food and Drug Administration (FDA) has granted Bionaut Labs orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in…
L.A. Biz recently sat down with CEO Michael Shpigelmacher to discuss the official launch of the company and the technology behind Bionauts. Bionaut Labs has captured the imagination of the…
In this video, Bionaut Labs CEO Michael Shpigelmacher joins Krisztina ‘Z’ Holly from Good Growth Capital for a fireside chat as part of LA MedTech Week. Shpigelmacher discusses the development…
First-in-class Bionaut™ treatment modality uses remote-controlled microscale robots to deliver biologics, nucleic acids, or small molecule therapies locally to targeted brain disease areas $20M financing led by Khosla Ventures supports…
